PMID- 36535009
OWN - NLM
STAT- MEDLINE
DCOM- 20221228
LR  - 20230813
IS  - 2542-5641 (Electronic)
IS  - 0366-6999 (Print)
IS  - 0366-6999 (Linking)
VI  - 135
IP  - 19
DP  - 2022 Oct 5
TI  - Neoadjuvant therapy for early human epidermal growth factor receptor 2 positive 
      breast cancer in China: A multicenter real-world study (CSBrS-015).
PG  - 2311-2318
LID - 10.1097/CM9.0000000000002197 [doi]
AB  - BACKGROUND: Pertuzumab has been approved for application in China by the National 
      Medical Products Administration, and both national and international guidelines 
      make recommendations for the use of neoadjuvant treatment with trastuzumab or 
      trastuzumab + pertuzumab plus chemotherapy regimens for patients with 
      indications. The goal of this study was to investigate the short-term clinical 
      efficacy of the neoadjuvant therapies trastuzumab and trastuzumab+pertuzumab for 
      patients with early human epidermal growth factor receptor 2 (HER2)-positive 
      breast cancer in China. METHODS: A real-world study was conducted using the 
      clinicopathological data of patients with early HER2-positive breast cancer who 
      were admitted to the member hospitals of the Chinese Society of Breast Surgery, 
      Chinese Surgical Society of Chinese Medical Association between March 2019 and 
      December 2020. This study analyzed the efficacy and tolerance of 
      trastuzumab+chemotherapy and trastuzumab+pertuzumab+chemotherapy in patients with 
      early HER2-positive breast cancer. The Response Evaluation Criteria in Solid 
      Tumors 1.1 was adopted to evaluate clinical efficacy. The pathological efficacy 
      was evaluated using the MillerPayne grade. The Common Terminology Criteria for 
      Adverse Events (version 5.0) was adopted to evaluate adverse events (AEs). The 
      propensity scores were subjected to propensity score matching using the R 
      language (1:1 matching with a maximum allowable difference of 0.05 between the 
      two groups). Efficacy was compared using the chi-square test, and correlation 
      analysis was performed using linear regression. RESULTS: A total of 1032 patients 
      with early HER2-positive breast cancer met the enrollment criteria and were 
      included in this study. Among these patients, 472 received neoadjuvant 
      trastuzumab+chemotherapy (the trastuzumab group), and 560 received neoadjuvant 
      trastuzumab+pertuzumab+chemotherapy (the trastuzumab+pertuzumab group). The 
      overall pathologic complete response (pCR) rate was 47.2% (487/1032), while the 
      pCR rates of the trastuzumab and trastuzumab+pertuzumab groups were 34.5% 
      (163/472) and 57.9% (324/560), respectively, and the difference was significant 
      (P < 0.001). The incidence of grade 4 AEs was 24/321 (7.5%) in the 
      trastuzumab+pertuzumab group, and there were no cases in which the left 
      ventricular ejection fraction decreased by more than 10%. CONCLUSIONS: Patients 
      in the trastuzumab+pertuzumab group had a higher pCR rate than those in the 
      trastuzumab group, and the toxic side effects were tolerable.
CI  - Copyright (c) 2022 The Chinese Medical Association, produced by Wolters Kluwer, 
      Inc. under the CC-BY-NC-ND license.
FAU - Cheng, Yuanjia
AU  - Cheng Y
AD  - Breast Disease Center, Peking University First Hospital, Beijing 100034, China.
FAU - Xiang, Hongyu
AU  - Xiang H
FAU - Xin, Ling
AU  - Xin L
FAU - Duan, Xuening
AU  - Duan X
FAU - Liu, Yinhua
AU  - Liu Y
CN  - Chinese Society of Breast Surgery (CSBrS), Chinese Society of Surgery of Chinese 
      Medical Association
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20221005
PL  - China
TA  - Chin Med J (Engl)
JT  - Chinese medical journal
JID - 7513795
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - P188ANX8CK (Trastuzumab)
SB  - IM
MH  - Female
MH  - Humans
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - *Breast Neoplasms/drug therapy
MH  - *Neoadjuvant Therapy
MH  - Receptor, ErbB-2/genetics
MH  - Stroke Volume
MH  - Trastuzumab/therapeutic use
MH  - Ventricular Function, Left
PMC - PMC9771321
COIS- None.
EDAT- 2022/12/20 06:00
MHDA- 2022/12/22 06:00
PMCR- 2022/10/05
CRDT- 2022/12/19 17:22
PHST- 2022/12/19 17:22 [entrez]
PHST- 2022/12/20 06:00 [pubmed]
PHST- 2022/12/22 06:00 [medline]
PHST- 2022/10/05 00:00 [pmc-release]
AID - 00029330-202210050-00007 [pii]
AID - CMJ-2021-3498 [pii]
AID - 10.1097/CM9.0000000000002197 [doi]
PST - epublish
SO  - Chin Med J (Engl). 2022 Oct 5;135(19):2311-2318. doi: 
      10.1097/CM9.0000000000002197.